State of the union for off-the-shelf (“In an ‘Allo or Bust’ Market, What’s Rising to the Top of theShelf?”)

Advanced Therapeutics
Wednesday, May 6, 2020 | 11:00 – 12:15 pm


  • Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health


  • Robert Ang, MD, MBA, President & CEO, Vor BioPharma Inc.
  • Jim Beitel, MD, PhD, SVP, Corporate Development, Fate Therapeutics Inc
  • Julia Chapman, Director, Alliance Management, Precision BioSciences
  • Thomas J. Farrell, President & CEO, Artiva Biotherapeutics
  • Maksim Mamonkin PhD, Assistant Professor, Pathology & Immunology Center for Cell and Gene Therapy, Baylor College of Medicine
  • Arthur Stril, VP Corporate Development, Cellectis